Advancing Newborn Genetic Screening with Machine Learning
A groundbreaking study demonstrates how machine learning can standardize gene selection in newborn genetic screening, improving accuracy and public health outcomes.
Over the past decade, efforts to enhance newborn genetic screening have expanded significantly, driven by advancements in genomic technologies. The BabySeq Project, initiated more than ten years ago, pioneered the integration of genomic sequencing results into newborn care, providing valuable insights into genetic conditions from birth. Today, more than 30 international programs are exploring the use of genomic sequencing (NBSeq) to identify genetic disorders early in life. However, these programs often vary widely in the genes they select for screening, leading to inconsistencies that can impact clinical outcomes.
A recent study by researchers at Mass General Brigham introduces a novel, data-driven approach to refining gene selection in NBSeq programs using machine learning. Published in Genetics in Medicine, the research emphasizes the importance of choosing relevant genes based on scientific evidence, natural history of conditions, and treatment effectiveness. Co-senior author Nina Gold, MD, highlighted that thoughtful gene selection is crucial for maximizing the benefits of genomic screening in newborns.
The study analyzed 4,390 genes across 27 NBSeq initiatives, revealing that only about 1.7%—74 genes—were included in over 80% of these programs. Key factors influencing gene inclusion were their presence on the U.S. Recommended Uniform Screening Panel, robust data on natural disease progression, and strong evidence supporting treatment options. To help standardize gene selection, the team developed a machine learning model incorporating 13 predictive factors. This model accurately forecasts gene inclusion decisions among various programs and provides a ranked list that can adapt to new scientific evidence and regional health priorities.
This innovative approach aims to harmonize NBSeq programs worldwide, ensuring more consistent and informed decision-making. As Green from Mass General Brigham noted, such tools can improve the impact of genetic screening by aligning practices with the latest research and public health goals, ultimately benefiting early diagnosis and intervention in newborns.
For more details, see the full study by Thomas Minten et al. in Genetics in Medicine (2025). Source: https://medicalxpress.com/news/2025-05-machine-newborn-genetic-screening.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Exploring Cancer Drugs as Potential Treatment for Alzheimer’s Disease
Emerging research suggests that existing cancer medications, letrozole and irinotecan, may help reverse brain changes in Alzheimer’s disease, offering a promising new treatment avenue.
The Enigma of Tickling: Unraveling a 2,000-Year-Old Mystery
Explore the fascinating science behind tickling, its neural mechanisms, evolutionary purpose, and its significance in social bonding and neurological research, a mystery still unsolved after 2,000 years.
New Insights into Peripheral Nerve Regeneration: The Role of Unknown RNA Molecules
New research uncovers hundreds of unknown RNA molecules that drive peripheral nerve regeneration, offering promising pathways for repairing nerve injuries and neurodegenerative diseases.
Major Recall: Over 67,000 Cases of Power Stick Deodorant Sold at Major Retailers
Over 67,000 cases of Power Stick deodorant sold at Dollar Tree, Walmart, and Amazon have been recalled due to manufacturing safety concerns. Consumers are advised to dispose of or return affected products.